Abstract 1935P
Background
The tertiary lymphoid structure (TLS) is an important part of the tumor microenvironment. It generates circulating immune cells and inhibits tumor growth and progression, which is closely related to the efficacy of immunotherapy.
Methods
This study collected the transcriptome information and clinical data of 10327 tumor samples and 730 normal samples of 33 cancer types from the TCGA database. Based on previous literature, three sets of TLS-related gene sets were selected and merged into the total TLS gene set. The TLS enrichment scores were calculated by the GSVA algorithm. Further, utilize TIMER 2.0 and CIBERSORTNE algorithms to analyze the distribution of tumor-infiltrating immune cells. Based on the enrichment score of TLS, sarcoma patients were divided into three TLS subtypes via the "hclust" R package. TLS-related prognostic core genes were screened via Lasso Cox and multivariate Cox regression and further used to establish the TLS-related prognostic signature. The public immunotherapy cohorts and our center immunotherapy patients were used to validate the efficacy of immunotherapy.
Results
The TLS gene set enrichment score established in this study is significantly positively correlated with immune cell infiltration such as T cells, B cells, and DC cells, which can reflect the TLS status in tumor tissue. Kaplan Meier survival analysis showed that patients with high TLS had better overall survival and progression-free survival compared to patients with low TLS. Through Lasso Cox and multivariate Cox regression, two TLS-related prognostic core genes (TNFRSF14 and DUSP9) were ultimately screened, and a TLS-related prognostic signature was established. Immunohistochemistry showed that the expression of TNFRSF14 was increased and the expression of DUSP9 was reduced in patients with soft tissue sarcoma who achieved optimal immunotherapy.
Conclusions
The TLS-Total gene set, TLS-related prognostic signature, TNFRSF14, and DUSP9 selected in this study can predict the prognosis of patients with soft tissue sarcoma. TNFRSF14 and DUSP9 are associated with immune cell infiltration, which can indicate the efficacy of immunotherapy and may become new predictive markers of immunotherapy efficacy.
Clinical trial identification
No
Editorial acknowledgement
No
Legal entity responsible for the study
The authors.
Funding
Natural Science Basic Research Program of Shaanxi (No. 2021JZ-35).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15